TIDMSYNC
RNS Number : 5221S
Syncona Limited
06 November 2019
Syncona Limited
Autolus Therapeutics to Present New Data at the ASH Annual
Meeting
06 November 2019
Syncona Ltd, a leading healthcare company focused on founding,
building and funding global leaders in life science, notes the
announcement that its portfolio company, Autolus Therapeutics Plc
(NASDAQ: AUTL) (Autolus), announced four oral and two poster
presentations related to its AUTO1, AUTO2 and AUTO3 programs at the
61st American Society of Hematology (ASH) Annual Meeting and
Exposition, to be held December 7-10, 2019 in Orlando, FL.
The announcement can be accessed on Autolus' investor website at
https://www.autolus.com/investor-relations and full text of the
announcement from Autolus is contained below.
[S]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel: +44 (0) 20 3981 7924
FTI Consulting
Brett Pollard / Ben Atwell / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of
investments of Syncona Limited. These statements and forecasts
involve risk and uncertainty because they relate to events and
depend upon circumstances that may or may not occur in the future.
There are a number of factors that could cause actual results or
developments to differ materially from those expressed or implied
by these forward-looking statements. In particular, many companies
in the Syncona Limited portfolio are conducting scientific research
and clinical trials where the outcome is inherently uncertain and
there is significant risk of negative results or adverse events
arising. In addition, many companies in the Syncona Limited
portfolio have yet to commercialise a product and their ability to
do so may be affected by operational, commercial and other
risks.
About Syncona
Syncona is a leading FTSE250 healthcare company focused on
founding, building and funding global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital,
and are established leaders in gene and cell therapy. We focus on
delivering dramatic efficacy for patients in areas of high unmet
need.
Autolus Therapeutics to Present New Data on Its Advanced
Programmed T Cell Therapies at the 61(st) ASH Annual Meeting
- Company to Present Four Oral Presentations and Two Posters
-
LONDON, UK, November 6, 2019 -- Autolus Therapeutics plc
(Nasdaq: AUTL), a clinical-stage biopharmaceutical company
developing next-generation programmed T cell therapies for the
treatment of cancer, announced four oral and two poster
presentations related to its AUTO1, AUTO2 and AUTO3 programs at the
61st American Society of Hematology (ASH) Annual Meeting and
Exposition, to be held December 7-10, 2019 in Orlando, FL.
"We are pleased that AUTO1 data will be presented in three oral
presentations at ASH. The data form the basis for our decision to
move AUTO1 into a pivotal clinical trial in adult ALL, our highest
priority program," said Dr. Christian Itin, chairman and chief
executive officer of Autolus. "We are also looking forward to
presenting data on our other hematological clinical programs at
ASH. These presentations will further illustrate the significant
progress we have made across our clinical portfolio this year."
The abstracts have been published today and are available on the
ASH website at
https://www.hematology.org/Annual-Meeting/Abstracts/.
The oral presentation details are as follows:
Title: AUTO1 - A novel fast off CD19CAR delivers durable
remissions and prolonged CAR T cell persistence with low CRS or
neurotoxicity in adult ALL
Presenter: Dr Claire Roddie
Session Date and Time: Saturday, December 7, 2:45 PM Eastern
Time
Title: AUTO1 - Therapy of pediatric B-ALL with a lower affinity
CD19 CAR leads to enhanced expansion and prolonged CAR T cell
persistence in patients with low bone marrow tumor burden, and is
associated with a favorable toxicity profile
Presenter: Dr Sara Ghorashian
Session Date and Time: Saturday, December 7, 2:30 PM Eastern
Time
Title: AUTO1 - Clonal dynamics of early responder and long-term
persisting CAR-T cells in humans
Presenter: Dr Luca Biasco
Session Date and Time: Saturday, December 7, 8:15 AM Eastern
Time
Title: AUTO3 - Ongoing Phase 1/2 ALEXANDER clinical trial in
patients with relapsed/refractory diffuse large B cell lymphoma
(DLBCL)
Presenter: Dr Kirit Ardeshna
Session Date and Time: Saturday, December 7, 3:15 PM Eastern
Time
The poster presentation details are as follows:
Title: AUTO2 - Phase 1 First-in-Human study of AUTO2, the first
chimeric antigen receptor (CAR) T cell targeting APRIL for patients
with relapsed/refractory Multiple Myeloma (RRMM)
Presenter: Dr Rakesh Popat
Session Date and Time: Sunday, December 8, 6:00 PM - 8:00 PM
Eastern Time
Title: AUTO3 - Phase 1/2 AMELIA clinical trial of AUTO3 in
patients with relapsed/refractory pediatric acute lymphoblastic
leukemia (pALL)
Presenter: Professor Persis Amrolia
Session Date and Time: Sunday, December 8, 6:00 PM - 8:00 PM
Eastern Time
About AUTO1
AUTO1 is a CD19 CAR T cell investigational therapy designed to
overcome the limitations in safety - while maintaining similar
levels of efficacy - compared to current CD19 CAR T cell therapies.
Designed to have a fast target binding off-rate to minimize
excessive activation of the programmed T cells, AUTO1 may reduce
toxicity and be less prone to T cell exhaustion, which could
enhance persistence and improve the T cells' abilities to engage in
serial killing of target cancer cells. In 2018, Autolus signed a
license agreement under which Autolus acquired global rights from
UCL Business plc (UCLB), the technology-transfer company of UCL, to
develop and commercialize AUTO1 for the treatment of B cell
malignancies. AUTO1 is currently being evaluated in two Phase 1
studies, one in pediatric ALL and one in adult ALL.
About AUTO3
AUTO3 is a programmed T cell therapy containing two independent
chimeric antigen receptors targeting CD19 and CD22 that have each
been independently optimized for single target activity. By
simultaneously targeting two B cell antigens, AUTO3 is designed to
minimize relapse due to single antigen loss in patients with B cell
malignancies. AUTO3 is currently being tested in pediatric ALL in
the AMELIA clinical trial and in diffuse large B cell lymphoma in
the ALEXANDER clinical trial.
About AUTO2
AUTO2 is the first dual-targeting programmed T cell product
candidate binding to two targets on multiple myeloma cells. AUTO2
uses a human ligand, known as APRIL, which binds to two antigens, B
cell Maturation Antigen, or BCMA, and the transmembrane activator
and CAML interactor, or TACI, both of which are expressed on the
surface of multiple myeloma cancer cells. AUTO2 is designed to
address a key escape route used by hematological cancers in
response to T cell therapies.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing
next-generation, programmed T cell therapies for the treatment of
cancer. Using a broad suite of proprietary and modular T cell
programming technologies, the company is engineering precisely
targeted, controlled and highly active T cell therapies that are
designed to better recognize cancer cells, break down their defense
mechanisms and eliminate these cells. Autolus has a pipeline of
product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information
please visit www.autolus.com.
Forward-Looking Statement
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts, and in
some cases can be identified by terms such as "may," "will,"
"could," "expects," "plans, " "anticipates," and "believes." These
statements include, but are not limited to, statements regarding
Autolus' financial condition and results of operations, as well as
statements regarding the anticipated development of Autolus'
product candidates, including its intentions regarding the timing
for providing further updates on the development of its product
candidates, and the sufficiency of its cash resources. Any
forward-looking statements are based on management's current views
and assumptions and involve risks and uncertainties that could
cause actual results, performance or events to differ materially
from those expressed or implied in such statements. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed
on November 23, 2018 as well as discussions of potential risks,
uncertainties, and other important factors in Autolus' future
filings with the Securities and Exchange Commission from time to
time. All information in this press release is as of the date of
the release, and the company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise, except as required by
law.
# # #
Investor and media contact:
Silvia Taylor
Vice President, Corporate Affairs and Communications
Autolus
+1-240-801-3850
s.taylor@autolus.com
UK:
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
PFUUNASRKBAARAA
(END) Dow Jones Newswires
November 06, 2019 09:20 ET (14:20 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2023 to Mar 2024